Biological tapering is cost-effective in patients with inflammatory arthritis in the biosimilar era: secondary analyses on the randomised BIODOPT trial
Authors:
- Line UhrenholtLine Uhrenholt
- Mads Engell Refstrup SørensenMads Engell Refstrup Sørensen
- Jan SørensenJan Sørensen
- Anne Estrup OlesenAnne Estrup Olesen
- Robin ChristensenRobin Christensen
- Lene DreyerLene Dreyer
- Bente GlintborgBente Glintborg
- Mads Nyhuus Bendix RaschMRMads Nyhuus Bendix Rasch
- Hans Christian HornHans Christian Horn
Open Access
- 8 August 2025
- journal article
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 1 (3) , 173-181
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk Fonden (0060515)
- Gigtforeningen
- Oak Foundation
- Parker Institute for Cancer Immunotherapy (OFIL-24-074)
This publication has 37 references indexed in Scilit:
- Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trialRheumatology International, 2024
- Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic EvaluationsValue in Health, 2022
- Shift From Adalimumab Originator to Biosimilars in DenmarkJAMA Internal Medicine, 2020
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis TrialValue in Health, 2017
- Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysisThe Lancet, 2015
- Reporting of Noninferiority and Equivalence Randomized TrialsJAMA, 2012
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- The impact of reducing dose frequency on health outcomesClinical Therapeutics, 2003
- The estimation of a preference-based measure of health from the SF-36Journal of Health Economics, 2002